Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).
Himisha Beltran(Dana-Farber Cancer Institute), Noura J. Choudhury(University of Chicago Medicine Comprehensive Cancer Center), Ann W. Gramza(Rapt Therapeutics (United States)), Hirva Mamdani(Wayne State University), Jonathan R. Thompson, Afshin Dowlati(University Hospitals of Cleveland), Melissa L. Johnson(Tennessee Oncology), Prantesh Jain(Roswell Park Comprehensive Cancer Center), Erin L. Schenk(University of Colorado Anschutz Medical Campus), Rachel E. Sanborn(Providence Portland Medical Center), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Banmeet S. Anand(Rapt Therapeutics (United States))
Cited by 37
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835